Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.
Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.
复制标题
DOI：
10.1007/s10620-021-06872-z
复制
发表时间：
2021-11
影响因子：
3.1
通讯作者：
Zhou Q
中科院分区：
文献类型：
--
作者：
Sun C;Chen Y;Hu L;Wu Y;Liang M;Ayaz Ahmed M;Bhan C;Guo Z;Yang H;Zuo Y;Yan Y;Zhou Q
据报道，法莫替丁可能为2019冠状病毒病（COVID-19）患者提供益处。然而，它是否能有效治疗COVID-19仍存在争议。本研究旨在探讨法莫替丁的使用是否与COVID-19患者的严重程度、死亡和插管风险降低相关。本研究已在国际前瞻性系统评价注册中心（PROSPERO）注册（ID：CRD 42020213536）。进行了全面检索，以识别截至2020年10月的相关研究。异质性分析采用I-squared统计量和Q检验。根据异质性的不同，采用随机效应或固定效应模型计算合并风险比（RR）和95%可信区间（CI）。还进行了亚组分析、敏感性分析和发表偏倚评估。纳入了5项研究，包括36，635例受试者。我们发现，法莫替丁的使用与2019冠状病毒病（COVID-19）患者进展为重度疾病、死亡和插管的风险降低相关，但无统计学显著性（汇总RR为0.82，95% CI = 0.52-1.30，P = 0.40）。法莫替丁在降低COVID-19患者发生严重疾病、死亡和插管的风险方面没有显著的保护作用。需要更多的原始研究来进一步阐明它是否与COVID-19患者的严重程度，死亡和插管风险降低有关。
Famotidine was reported to potentially provide benefits to Coronavirus Disease 2019 (COVID-19) patients. However, it remains controversial whether it is effective in treating COVID-19. This study aimed to explore whether famotidine use is associated with reduced risk of the severity, death, and intubation for COVID-19 patients. This study was registered on International Prospective Register of Systematic Reviews (PROSPERO) (ID: CRD42020213536). A comprehensive search was performed to identify relevant studies up to October 2020. I-squared statistic and Q-test were utilized to assess the heterogeneity. Pooled risk ratios (RR) and 95% confidence intervals (CI) were calculated through the random effects or fixed effects model according to the heterogeneity. Subgroup analyses, sensitivity analysis, and publication bias assessment were also conducted. Five studies including 36,635 subjects were included. We found that famotidine use was associated with a statistically non-significant reduced risk of progression to severe disease, death, and intubation for Coronavirus Disease 2019 (COVID-19) patients (pooled RR was 0.82, 95% CI = 0.52–1.30, P = 0.40). Famotidine has no significant protective effect in reducing the risk of developing serious illness, death, and intubation for COVID-19 patients. More original studies are needed to further clarify whether it is associated with reduced risk of the severity, death, and intubation for COVID-19 patients.
登录
查看更多内容
DOI：
10.1136/bmj.b2535
发表时间：
2009-07-21
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
影响因子：
7.3
作者：
Krystel-Whittemore M;Dileepan KN;Wood JG
通讯作者：
Wood JG
影响因子：
168.9
作者：
Huang, Chaolin;Wang, Yeming;Cao, Bin
通讯作者：
Cao, Bin
影响因子：
56.9
作者：
Anand, K;Ziebuhr, J;Hilgenfeld, R
通讯作者：
Hilgenfeld, R
DOI：
10.1136/bmj.d671
发表时间：
2011-02-22
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Ronksley PE;Brien SE;Turner BJ;Mukamal KJ;Ghali WA
通讯作者：
Ghali WA